Drug Search Results
More Filters [+]

AntiBKV

Alternative Names: AntiBKV, Anti-BK polyomavirus (AntiBKV)
Latest Update: 2024-02-05
Latest Update Note: News Article

Product Description

Memo Therapeuitcs AG’s (“MTx”) lead program, AntiBKV, is a highly effective and safe neutralizing antibody to treat BK virus infection in kidney transplant recipients. MTx’ pipeline consists of additional therapeutic antibodies focusing on infectious diseases, such as cytomegalovirus (“CMV”), undisclosed immuno-oncology targets as well as a partnership with Ono Pharmaceutical. (Sourced from: https://memo-therapeutics.com/pipeline.html)

Mechanisms of Action: Unknown

Novel Mechanism: No

Modality: Antibody

Route of Administration: N/A

FDA Designation: Fast Track - Renal Transplant *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Memo Therapeutics
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for AntiBKV

Countries in Clinic: Australia, United States

Active Clinical Trial Count: 2

Highest Development Phases

Phase 3: Kidney Transplant

Phase 1: Kidney Diseases|Opportunistic Infections|Polyomavirus Infections|Renal Transplant

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

SAFE KIDNEY II

P3

Recruiting

Kidney Transplant

2024-11-24

55%

SAFE KIDNEY I

P1

Completed

Opportunistic Infections|Renal Transplant|Polyomavirus Infections|Kidney Diseases|Kidney Transplant

2022-12-05

Recent News Events